Biopharmaceutical Third Party Logistics (Distribution Management, Packaging & Labeling, Transportation, Warehousing) Market Research And Global Forecast Report 2026-2032

(MENAFN- GlobeNewsWire - Nasdaq) New therapies and regulations are redefining biopharma logistics, creating opportunities in cold chain integrity, digital tracking, and strategic vendor collaborations globally.

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical Third Party Logistics Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets's offering.

The Biopharmaceutical Third Party Logistics Market is projected to grow from USD 140.03 billion in 2025 to USD 161.04 billion in 2026 and is forecast to reach USD 384.23 billion by 2032, representing a compound annual growth rate (CAGR) of 15.51%.

The biopharmaceutical third-party logistics market is experiencing significant evolution as new therapies, regulatory changes, and technological advancements redefine expectations for global supply chain management.

This expansion reflects escalating demand for cold chain integrity, specialized handling, and advanced supply network visibility as product complexity rises across biological and gene-based modalities. Increased regulatory focus and evolving patient delivery models further accelerate the need for strategic logistics partnerships.

Key Takeaways

• Rising product complexity and patient-focused supply models require logistics partners with advanced cold chain and clinical support capabilities.
• Regulatory scrutiny is intensifying, pushing for improved traceability, standardized validation, and audit-ready data management throughout the logistics life cycle.
• Technology advancements such as active packaging and telemetry-enabled monitoring enable real-time shipment visibility and dynamic risk mitigation, reducing spoilage and operational disruptions.
• Strategic vendor selection increasingly prioritizes cross-functional collaboration between manufacturing, clinical, quality, and commercial teams to ensure alignment with therapeutic and market requirements.
• Specialized assets, digital orchestration, and demonstrated experience with high-value biologics now drive competitive differentiation and long-term supplier relationships.

Scope & Segmentation

• Service Types: Distribution Management, Packaging & Labeling, Transportation, Warehousing
• Packaging & Labeling: Active Packaging (Controlled Atmosphere Packaging, Refrigerated Containers), Labeling Services, Passive Packaging
• Transportation Modes: Air Transport (Express, Standard), Rail Transport, Road Transport, Sea Transport
• Warehousing Categories: Ambient Storage, Cold Storage
• Temperature Ranges: Ambient, Chilled (Monitored, Standard), Controlled Room Temperature (Monitored, Standard), Frozen (Standard, Ultra Frozen)
• Mode Of Transportation: Air Freight (Express, Standard), Rail Freight, Road Transport (Full Truck Load, Less Than Truck Load), Sea Freight (Full Container Load, Less Than Container Load)
• End Users: Biopharmaceutical Manufacturers, Contract Manufacturing and Research Organizations, Diagnostic Laboratories, Hospitals & Clinics (Community, Research)
• Product Types: Cell Therapies (Dendritic Cell, Stem Cell), Gene Therapies, Monoclonal Antibodies, Recombinant Proteins, Vaccines (Inactivated, Live Attenuated)
• Packaging Types: Active (Refrigerated Containers, Temperature Controlled Shippers), Passive (Insulated Boxes, Thermal Blankets)
• Regions: Americas, Europe Middle East & Africa, Asia-Pacific

Why This Report Matters

• Empowers executive stakeholders to benchmark logistics sourcing, network design, and risk management strategies for complex biologics.
• Clarifies the impact of regulatory, product, and tariff shifts, guiding resilient investment in validated cold chain infrastructure and digital solutions.
• Delivers actionable insights for aligning operations, compliance, and commercial goals in a rapidly transforming market environment.

Conclusion

Meeting future demands in biopharmaceutical logistics requires alignment between technology, capability-based sourcing, and collaborative strategic planning. Organizations investing in validated and adaptable cold chain systems are positioned to protect product quality, reduce risk, and ensure timely patient access.

Key Attributes:

Report Attribute	Details
No. of Pages	183
Forecast Period	2026 - 2032
Estimated Market Value (USD) in 2026	$161.04 Billion
Forecasted Market Value (USD) by 2032	$384.23 Billion
Compound Annual Growth Rate	15.5%
Regions Covered	Global

Companies Featured

• Agility Public Warehousing Company K.S.C.P.
• Bollore SE
• C.H. Robinson Worldwide, Inc.
• Cardinal Health, Inc.
• Cencora, Inc.
• CEVA Logistics AG
• Cryoport, Inc.
• DB Schenker Logistics Germany AG & Co. KG
• Deutsche Post AG
• DSV Panalpina A/S
• EVERSANA Life Science Services LLC
• Expeditors International of Washington, Inc.
• FedEx Corporation
• KLN Logistics Group Limited
• Kuehne + Nagel International AG
• LOGISTEED, Ltd.
• McKesson Corporation
• NIPPON EXPRESS HOLDINGS, INC.
• SF Holding Co., Ltd.
• Thermo Fisher Scientific Inc.
• United Parcel Service, Inc.
• XPO, Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Biopharmaceutical Third Party Logistics Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN09042026004107003653ID1110961361